Enhanced antithrombotic effects with the combination of rivaroxaban - a novel, oral, direct factor Xa inhibitor and clopiclogrel, in animal models

被引：0
|
作者：
Perzborn, E. [1 ]
Fischer, E. [1 ]
Lange, U. [1 ]
机构：
[1] Bayer HealthCare, Pharma R&D Discovery Res, Wuppertal, Germany
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2008年 / 141卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
220
引用
收藏
页码：81 / 81
页数：1
相关论文
共 50 条
  • [31] Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats
    Morishima, Yoshiyuki
    Honda, Yuko
    Kamisato, Chikako
    Tsuji, Naoki
    Kita, Akemi
    Edo, Naoko
    Shibano, Toshiro
    THROMBOSIS RESEARCH, 2012, 130 (03) : 514 - 519
  • [32] Inhibition of thrombin generation in human plasma by rivaroxaban, an oral, direct Factor Xa inhibitor
    Perzborn, E.
    Harwardt, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 379 - 379
  • [33] The mechanism of action of rivaroxaban - an oral, direct Factor Xa inhibitor - compared with other anticoagulants
    Samama, Meyer Michel
    THROMBOSIS RESEARCH, 2011, 127 (06) : 497 - 504
  • [34] Comparison of YM150, an oral, direct factor Xa inhibitor, with other antithrombotic agents in thrombosis models
    Saitoh, Minori
    Kaku, Seiji
    Iwatsuki, Yoshiyuki
    Sasamata, Masao
    Miyata, Keiji
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 213P - 213P
  • [35] Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans
    Weinz, C.
    Schwarz, T.
    Kubitza, D.
    Mueck, W.
    Lang, D.
    DRUG METABOLISM AND DISPOSITION, 2009, 37 (05) : 1056 - 1064
  • [36] Antithrombotic and anticoagulant effects of direct factor Xa inhibitor darexaban in rat and rabbit models of venous thrombosis
    Kaku, Seiji
    Uemura, Toshio
    Saitoh, Minori
    Suzuki, Ken-ichi
    Iwatsuki, Yoshiyuki
    Funatsu, Toshiyuki
    Kawasaki, Tomihisa
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 699 (1-3) : 40 - 47
  • [37] Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity
    Graff, Jochen
    von Hentig, Nils
    Misselwitz, Frank
    Kubitza, Dagmar
    Becka, Michael
    Breddin, Hans-Klaus
    Harder, Sebastian
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (11): : 1398 - 1407
  • [38] Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits
    Wong, P. C.
    Watson, C. A.
    Crain, E. J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (10) : 1736 - 1741
  • [39] Rivaroxaban: a novel oral factor Xa inhibitor to prevent stroke in nonvalvular atrial fibrillation
    Vitin, Leslie
    Quinto, Emily
    Kirwin, Jennifer
    FORMULARY, 2011, 46 (07) : 257 - +
  • [40] Antithrombotic efficacy of BAY 59-7939 - an oral, direct Factor Xa inhibitor - compared with fondaparinux in animal arterial thrombosis and thromboembolic death models
    Perzborn, E.
    Arndt, B.
    Harwardt, M.
    Lange, U.
    Trabandt, A.
    EUROPEAN HEART JOURNAL, 2005, 26 : 481 - 481
12345